AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02761811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Description: Radiofrequency ablation of renal arterial sympathetic nerves
Study NCT03702478 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: No intervention only observational
Study NCT01466270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil hydrochloride
Description: Given PO
Study NCT01466270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03984695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE-WOMEN
Description: SHE-WOMEN is a text-Web intervention designed to increase jail-involved women's health literacy, reduce risk, and increase screening for prevention of cervical cancer, breast cancer, unintended pregnancy, and sexually transmitted infections.
Study NCT03901924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume Support Mode Mechanical Ventilation
Description: This is a spontaneous mode of mechanical ventilation that depends on the patient's efforts. A target volume (6 cc/kg of IBW), PEEP and FiO2 are set by the medical team, and the ventilator varies the inspiratory pressure support with each breath to achieve the target volume. The respiratory rate is fully dependent on the patient. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
Study NCT03901924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assist Control Mode Mechanical Ventilation
Description: This is a controlled mode of mechanical ventilation that is independent of patient's efforts. A tidal volume (6 cc/kg of IBW), respiratory rate, PEEP and FiO2 are set by the medical team. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
Study NCT00424905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: 2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
Study NCT03436940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Discharge Planning (RDP)
Description: All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
Study NCT02404675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Study NCT02404675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: icotinib
Study NCT01796769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) in sleep apnea patients
Description: Usual CPAP treatment in sleep apnea patients
Study NCT01796769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) in sleep apnea patients
Description: CPAP treatment with telemedicine system
Study NCT01953523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Administration of autologous adipose derived SVF
Description: Intra-venous, intra-articular, and soft tissue injection delivery of SVF
Study NCT03403010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation-specific gaming platform
Description: The rehabilitation specific gaming software was developed as part of the ICT4rehab project with partners from the Vrije Universiteit Brussel and the University Libre de Bruxelles. The ICT4Rehab puts several ICT tools supporting 2/3D user interaction into place. The games can be controlled using a Kinect camera system (Microsoft(®) (Redmond, WA) Kinect™) or a Wii balance board (® NintendoTM, Japan), depending on the choice of the therapist and the needs of the child.
Study NCT02724449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavilon Advanced Barrier Film
Description: Cavilon Advanced Barrier Fim's application applied twice a week
Study NCT00664885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Sensitive Collaborative Treatment
Description: a collaborative care model, for treating depressed patients in general medical care
Study NCT00587678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40mg each night
Study NCT00587678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10mg daily
Study NCT00587678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe
Description: 40mg/10mg each night
Study NCT01324661 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ostracism
Description: Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
Study NCT00997802 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CT colonography and optical colonoscopy
Description: All patients will undergo CT colonography and optical colonoscopy.
Study NCT00652795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate
Description: Tablets, 150 mg, single-dose
Study NCT00652795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monodox
Description: Capsules 50 mg (3 x 50 mg dose), single-dose
Study NCT03501225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ozone
Description: After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with ozonated water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with ozonated water according to randomization. The suture was then performed.
Study NCT03501225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water
Description: After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with redistilled water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with redistilled water according to randomization. The suture was then performed.
Study NCT04236674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy thermomechanical device
Description: Buzzy thermomechanical device placed near intervention site.
Study NCT04236674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Selection
Description: Patient specified procedural music
Study NCT02238119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + formoterol combination
Study NCT02238119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study NCT02238119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Study NCT00920855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m\^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.~Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle.
Study NCT00920855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib was administered at a dose of 1.0 mg/m\^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
Study NCT00356681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 706 placebo
Description: Blinded placebo
Study NCT00356681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
Study NCT00356681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
Study NCT00356681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
Study NCT00356681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
Study NCT00356681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
Study NCT04163575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: :Anti-CD22-CAR
Description: Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
Study NCT05586919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Puncture Repair / Ethanol
Description: Ethanol is an organic compound that will be injected in the venous malformation as a sclerotherapy by Direct Puncture Repair
Study NCT05586919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Puncture Repair / Polidocanol
Description: Polidocanol is a sclerosing agent that will be injected in the venous malformation by Direct Puncture Repair
Study NCT02347839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gefitinib-surgery-gefitinib
Description: neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
Study NCT02489539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® EXCLUDER® Conformable AAA Endoprosthesis
Description: Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
Study NCT00881114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
Study NCT00881114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
Study NCT05187078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allis clamp
Description: Physicians utilized an Allis clam for cervical stabilization during IUD placement.
Study NCT05187078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-tooth tenaculum
Description: Physicians utilized a single-tooth tenaculum clam for cervical stabilization during IUD placement.
Study NCT03342417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg administered by IV infusion over 30 minutes
Study NCT03342417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.
Study NCT02936674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light - standard
Description: Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution
Study NCT02936674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light - alternate
Description: Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)
Study NCT04017065 — intervention group
Intervention type: DEVICE
Intervention: DePuy Synthes MAXFRAMETM system
Description: Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
Study NCT01330407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreserved skin allografts.
Study NCT01330407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultured Epidermal Autografts
Study NCT02594254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Gel
Description: Antimicrobial peptide
Study NCT02025179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide 20 ug daily Sub-Q over 12 months
Study NCT02025179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Vibration 10 min/day for 12 months
Study NCT02435004 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Modulation Axium™
Description: The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).~If during the trial treatment the pain will decrease significantly (> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket.
Study NCT03123666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMCSF
Description: GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer
Study NCT03123666 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to GMCSF will be given
Study NCT05570266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Cancer Risk Prediction Software
Description: Genotyping of known breast cancer-related markers (313 variants) will be conducted using a microarray genotyping chip (Genetic Risk). Survey answers will determine Gail Model scores and thus Clinical Risk Score.
Study NCT00424944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMZ2 (malaria vaccine)
Description: 100 micrograms of GMZ2 in each vaccination
Study NCT00424944 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GMZ2 (malaria vaccine)
Description: 100 micrograms of GMZ2 in each vaccination
Study NCT00424944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMZ2 malaria vaccine
Description: 100 micrograms of GMZ2
Study NCT00424944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Verorab vaccine
Description: Anti-rabies vaccine
Study NCT00424944 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Verorab vaccine
Description: Anti-rabies vaccine
Study NCT02434822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Description: 1.5 mL, Oral administration
Study NCT03546556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothymidine (FLT)
Description: A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
Study NCT02594254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00608075 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lithium
Description: 600 mg - 1800 mg per day
Study NCT00608075 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lithium
Description: 600 - 1800 mg
Study NCT02863874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VicrylPlus®
Description: Suture
Study NCT02863874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl®
Description: Suture
Study NCT03083457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation or amine administration
Description: Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
Study NCT03554928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging
Description: Participants will receive a 60 minute magnetic resonance imaging assessment
Study NCT03083457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthetic
Description: Total intravenous anesthesia with a standard protocol
Study NCT02936817 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aerobika® Device
Description: For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
Study NCT02936817 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: HRCT scans
Description: A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
Study NCT03499093 — intervention group
Intervention type: OTHER
Intervention: OES
Description: The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test.
Study NCT02102113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose THC
Description: Subjects will receive 0.018 mg/kg over 20 minutes.
Study NCT02102113 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Low Dose THC
Description: Subjects will receive 0.018 mg/kg over 20 minutes.
Study NCT01833559 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary control
Study NCT01833559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
Study NCT03117855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT03117855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03117855 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioembolization
Description: Undergo yttrium Y-90 radioembolization
Study NCT01440855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIS (Cancer Information Service) Information Sheet
Description: CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
Study NCT03083457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: 3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure